Incannex Healthcare (IXHL) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SCYNEXIS (SCYX) has outperformed Incannex Healthcare (IXHL) over the past year, losing 32.1% versus a loss of 75.3%. SCYNEXIS is the larger company by market cap ($42.0 million vs $40.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IXHL | SCYX |
|---|---|---|
| Share price | $3.20 | $4.22 |
| Market cap | $40.14M | $41.99M |
| 1-day change | +0.63% | -11.72% |
| YTD return | -70.20% | -16.53% |
| 1-year return | -75.31% | -32.11% |
| 5-year return | — | -90.53% |
| EPS (TTM) | $-1.66 | $-0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.91 | $9.12 |
| 52-week low | $2.49 | $3.53 |
| Distance from 52-week high | -78.54% | -53.73% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +483.75% | +760.90% |
| Average volume | 94.75K | 279.10K |
| Shares outstanding | 12.54M | 9.95M |
| Employees | 12 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SCYX has outperformed IXHL by 43.2 percentage points over the past year.
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Healthcare · Drug Manufacturers - Specialty & Generic · 18 employees
IXHL vs SCYX FAQ
Which is bigger, Incannex Healthcare or SCYNEXIS?
SCYNEXIS (SCYX) is larger, with a market capitalization of $41.99M compared with $40.14M for Incannex Healthcare (IXHL).
Which stock has performed better over the past year, IXHL or SCYX?
SCYX returned -32.11% over the past 12 months, compared with -75.31% for IXHL (price return, excluding dividends). Past performance does not predict future results.
Are Incannex Healthcare and SCYNEXIS in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.